Trial Information

Evaluation of a Multi-faceted Intervention to Improve Continuity of Care for Patients With Lung Cancer

Lung cancer patients from both the intervention and the control group will complete
validated questionnaires at baseline and then after 3, 6, 9, 12, 15 and 18 months (or until
death for those with a survival of less than 18months) to assess their perceived
collaboration between their FP and the oncology team (from an adaptation of Nielsen et al.'s
validated questionnaire (2003)), their quality of life (from the EORTC-QLQ-C30), pain and
other symptom relief (from the EORTC-QLQ-LC13), their level of distress, anxiety and
depression (from the HADS), their self-efficacy (from an adaptation of Lorig et al.'s
validated questionnaire (1996)). Several processes of care will also be measured at the same
intervals: number of exchanges of information, number of visits to FP, number of
answered/unanswered calls from FP, delay to return patients' calls, responsibility for care
by FP at the terminal phase of cancer, service utilization (ER visits, hospitalization,
community health services). The investigators will also measure in patients' principal
family caregivers, their perceived collaboration between FP and the oncology team (same
questionnaire than the one used for patients but adapted to family caregivers), their
distress (from the IDPESQ), psychological burden (from the CBS-EOLC) and self-efficacy (same
questionnaire than the one used for patients but adapted to family caregivers . Finally,
measures related to FP will include their perceived collaboration with the oncology team
(same questionnaire than the one used for patients and family caregivers but adapted to
FPs).